Stifel Financial Corp increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 5.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 211,758 shares of the company’s stock after purchasing an additional 10,024 shares during the quarter. Stifel Financial Corp’s holdings in Zoetis were worth $13,506,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently modified their holdings of ZTS. FDO Partners LLC purchased a new position in Zoetis during the third quarter worth $1,828,000. Tredje AP fonden increased its position in Zoetis by 14.1% during the third quarter. Tredje AP fonden now owns 357,127 shares of the company’s stock worth $22,770,000 after buying an additional 44,239 shares in the last quarter. Commerzbank Aktiengesellschaft FI purchased a new position in Zoetis during the third quarter worth $260,000. Skandinaviska Enskilda Banken AB publ increased its position in Zoetis by 2.3% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 253,926 shares of the company’s stock worth $16,190,000 after buying an additional 5,700 shares in the last quarter. Finally, KBC Group NV increased its position in Zoetis by 42.5% during the third quarter. KBC Group NV now owns 409,592 shares of the company’s stock worth $26,115,000 after buying an additional 122,247 shares in the last quarter. 93.33% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have weighed in on ZTS shares. Cantor Fitzgerald reissued a “buy” rating and set a $75.00 price target on shares of Zoetis in a research report on Wednesday, September 6th. Stifel Nicolaus reissued a “buy” rating and set a $65.00 price target on shares of Zoetis in a research report on Friday, September 1st. Piper Jaffray Companies set a $73.00 price target on Zoetis and gave the stock a “buy” rating in a research report on Friday, August 25th. Cowen set a $70.00 price objective on Zoetis and gave the company a “buy” rating in a research report on Thursday, August 24th. Finally, BidaskClub downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 20th. One analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company. Zoetis currently has an average rating of “Buy” and an average target price of $68.24.
Shares of Zoetis Inc. (NYSE ZTS) traded up $0.24 during trading hours on Friday, hitting $71.88. The stock had a trading volume of 1,640,004 shares, compared to its average volume of 2,097,440. The stock has a market capitalization of $34,909.33, a P/E ratio of 32.86, a P/E/G ratio of 2.15 and a beta of 1.06. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. Zoetis Inc. has a twelve month low of $50.57 and a twelve month high of $72.79.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.02. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.52 earnings per share. research analysts forecast that Zoetis Inc. will post 2.37 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Thursday, November 9th were issued a $0.105 dividend. This represents a $0.42 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date of this dividend was Wednesday, November 8th. Zoetis’s payout ratio is currently 22.11%.
TRADEMARK VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/09/stifel-financial-corp-raises-position-in-zoetis-inc-zts.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.